Assistant Professor of Population Health @nyugrossman fresh twitter start... my original account got bitcoin hacked :\
Joined November 2020
- Tweets35
- Following238
- Followers212
- Likes148
Sunita Desai retweeted
We have a great line-up for 2026 NYC Health Economics Day @NYUWagner on Friday, May 1 - Link to RSVP below! Co-organized w/@MJ_Dickstein @sunitamd @amy_m_bond @jnvanparys
Sunita Desai retweeted
I am excited to share our new WP on soda taxes with/ @sunitamd, @BrianElbel, @MarieABragg, @PasqualeRummo, T.Mijanovich, B.Weitzman, and E.Wu is out today.
papers.ssrn.com/sol3/papers.…
Sunita Desai retweeted
NYC Health Econ Day is coming to @NYUStern May 3! We'll have four great paper presentations with lots of time for folks to chat.
RSVP here: docs.google.com/forms/d/e/1F…
More info: stern.nyu.edu/experience-ste…
Organizers: @amy_m_bond @sunitamd @MJ_Dickstein @LaurawherryR + me
ALT NYC Health Econ Day conference program, available from info website link in post
Sunita Desai retweeted
Yippeeeeeee aeaweb.org/articles?id=10.12…
Many thanks to wonderful mentors @Ateevm @leorahorwitzmd + a dynamic cross-functional team spanning operations, pharmacy, IT, and research + and @nyulangone for facilitating this RCT. It was my first RCT and a lot of fun! 7/7
Nonetheless, results suggest providing patient-specific out-of-pocket cost info at the point of order entry can influence rx. This stands in contrast to many consumer facing price tools which gained less traction. Engaging physicians on issues of cost and value is important! 5/7
Major reasons RTPB recommendations were not made for majority of rx's included pt’s info could not be linked to the underlying RTPB database containing benefit design and cost information + the rx not considered to have an alternative. 4/7
We randomized RTPB across practices. RTPB led to an 11% reduction in out-of-pocket costs among rx with alts. In the highest cost drug classes, RTPB led to 40% lower out-of-pocket costs. Big caveat is that RTPB made recommendations for a small pct (~4%) of all orders. 3/7
RTPB uses pt-specific benefit info to recommend clinically-appropriate alternatives with lower out-of-pocket costs at the point of prescribing. Recommended alts could be different drugs (pre-determined by the pt's PBM), greater days' supply, and/or mail-order prescriptions 2/7
New study w/@leorahorwitzmd @Ateevm+ many others: RCT across NYU Langone practices to study the effects of real-time prescription benefits (RTPB) on out-of-pocket costs. tinyurl.com/2p8wmzs4 1/7
We can’t really say whether the extra diagnostic codes reflect inappropriate upcoding or more accurate coding by the hospitals with higher private insurance mix. But our work does highlight a previous unexamined cross-payer externality. 3/3
We find yes, it does.Following Medicaid pts with admissions at >1 hospitals, the same pt was coded more severely when admitted at a hospital with a higher private mix. We did several analyses to try to get rid of potential sources of bias that could be driving our results. 2/3
Fun paper led by the dynamic @kacie_dragan. Does hospitals' private payor mix affect dx coding intensity in Medicaid? The idea was that hospitals with higher shares of private pts may have more incentive to invest in intensive coding infrastructure and practices. 1/3
On a personal note, this project is dear to me, as it’s a collaboration with some of my favorite people & mentors — together, all in one paper! (big thanks to Sherry, John, @sunitamd ) — and a very fond reminder of the fun I had at @NYUWagner !
Sunita Desai retweeted
Interesting paper by @sunitamd +team in @JAMAHealthForum. 340B gives drug discounts to hospitals that treat low-income patients. Instead, growth in 340B has in rich and white areas. Opposite of 340B's goal! ja.ma/3OkfqM6
Sunita Desai retweeted
And now tagging @sunitamd
Fascinating analysis of how the financial incentives established by #340B program may be affecting uptake of #biosimilar drugs.
If actually enforced, this Rule could be an important step forward in making real health care prices available to market participants. 4/3
Hospitals have unsurprisingly resisted, but oversight should not be hard, and the onus should be on hospitals to demonstrate compliance. Penalties were raised to $10/day/bed (up to $5.5K/day), but last I heard penalties haven’t been enforced. 3/3